France-based ophthalmic ultrasound and laser devices company Quantel Medical has obtained US Food and Drug Administration (FDA) approval for the clinical use of its selective laser trabeculoplasty (SLT) glaucoma laser Solutis, which is designed to reduce intraocular pressure in glaucoma patients.
The 532nm laser targets and is absorbed by pigmented cells, inducing a healing response that restores functionality of the trabecular meshwork while reducing intraocular pressure.
SLT is a gentle laser therapy compared to other traditional laser procedures. It is considered effective for first-line, adjunct or secondary line treatments.
The laser energy’s gentle application enables the treatment to be repeated and does not cause ocular and systemic side effects or have any compliance issues as is generally found in cases of glaucoma drugs.
Quantel Medical CEO Jean-Marc Gendre said: "Solutis has proven to be an attractive laser solution worldwide, and we are proud to now offer this laser alongside our robust line of multispot and YAG lasers."
The approval follows the expiration of a patent issued to Massachusetts General Hospital that restricted laser manufacturers from selling SLT within the US.
Quantel’s Solutis laser has been in use since 2007 outside the US.